# Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors

> **NCT02220049** · PHASE1 · COMPLETED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 18 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT02220049
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02220049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02220049, "Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02220049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*